2024
Construction and performance of a clinical prediction rule for ureteral stone without the use of race or ethnicity: A new STONE score
Moore C, Gross C, Hart L, Molinaro A, Rhodes D, Singh D, Baloescu C. Construction and performance of a clinical prediction rule for ureteral stone without the use of race or ethnicity: A new STONE score. Journal Of The American College Of Emergency Physicians Open 2024, 5: e13324. PMID: 39524039, PMCID: PMC11543628, DOI: 10.1002/emp2.13324.Peer-Reviewed Original ResearchClinical prediction ruleArea under the receiver operating characteristic curveSTONE scoreMultivariate logistic regressionUreteral stonesComputed tomographyPrediction ruleUncomplicated renal colicKidney stonesReceiver operating characteristic curveLogistic regressionNon-black raceDiagnosis of kidney stonesGross hematuriaMicroscopic hematuriaRenal colicPotential adverse effectsDiagnostic accuracyHematuriaClinical algorithmMale genderProspective dataClinical accuracyRetrospective dataCharacteristic curveDisparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic
Siddique S, Wang R, Gaddy J, Stempel J, Warren J, Gross C, Ma X. Disparities in Colorectal Cancer Screening Before and After the Onset of the COVID Pandemic. Journal Of General Internal Medicine 2024, 1-9. PMID: 39495455, DOI: 10.1007/s11606-024-09153-3.Peer-Reviewed Original ResearchRisk of CRCSocioeconomic statusCRC screeningArea-level socioeconomic measuresArea-level socioeconomic factorsHigher risk of CRCArea residentsColorectal cancer screeningSocial deprivation indexHigher socioeconomic statusLow socioeconomic statusEthnic minoritized populationsDifference-in-differences analysisPost-onset periodDesignRetrospective cohort studyDeprivation indexCancer screeningSocioeconomic measuresPrivately insured individualsMetropolitan area residentsCOVID pandemicScreen useAverage riskCompare disparitiesSocioeconomic factorsPhysicians, the Homelessness Crisis, and Public Health—All Hands on Deck
Gross C, Gluck A, Corbie G. Physicians, the Homelessness Crisis, and Public Health—All Hands on Deck. JAMA Internal Medicine 2024, 184 PMID: 39401048, DOI: 10.1001/jamainternmed.2024.5341.Peer-Reviewed Original ResearchAmbient Temperature and Stroke Risk Among Adults Aged 18-64 Years A Case-Crossover Study
Chu L, Wang R, Gross C, Chen K, Ma X. Ambient Temperature and Stroke Risk Among Adults Aged 18-64 Years A Case-Crossover Study. Journal Of The American College Of Cardiology 2024 PMID: 39453364, DOI: 10.1016/j.jacc.2024.08.058.Peer-Reviewed Original ResearchLong-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed treatmentDisease courseUSPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years
Siddique S, Wang R, Yasin F, Gaddy J, Zhang L, Gross C, Ma X. USPSTF Colorectal Cancer Screening Recommendation and Uptake for Individuals Aged 45 to 49 Years. JAMA Network Open 2024, 7: e2436358. PMID: 39361285, PMCID: PMC11450516, DOI: 10.1001/jamanetworkopen.2024.36358.Peer-Reviewed Original ResearchConceptsUS Preventive Services Task ForceUS Preventive Services Task Force recommendationsColorectal cancer screening uptakeAverage-risk individualsScreening uptakeHigher socioeconomic statusSocioeconomic statusScreening recommendationsColorectal cancerColorectal cancer screening recommendationsPreventive Services Task ForceCohort studyCancer screening recommendationsScreening uptake ratesInterrupted time series analysisLow socioeconomic statusPrivate insurance beneficiariesScreening ratesSocioeconomic disparitiesRetrospective cohort studyMain OutcomesPotential disparitiesEvaluate changesClaims dataAbsolute changeIs federal housing assistance associated with earlier-stage cancer diagnosis? Evidence from the new SEER-Medicare and US Department of Housing and Urban Development data linkage.
Yabroff R, Blackford A, Fan Q, Hussaini S, Chen K, Polsky D, Katana Ogongo M, Warren J, Gross C, Pollack C. Is federal housing assistance associated with earlier-stage cancer diagnosis? Evidence from the new SEER-Medicare and US Department of Housing and Urban Development data linkage. Journal Of Clinical Oncology 2024, 20: 85-85. DOI: 10.1200/op.2024.20.10_suppl.85.Peer-Reviewed Original ResearchFederal housing assistanceHousing assistanceUS Department of HousingDepartment of HousingSocial determinants of healthDeterminants of healthCancer outcomesSEER-MedicareHousing insecurityCancer diagnosisSocioeconomic status indexSocial determinantsRural/urban residenceAdministrative dataMarital statusLogistic regression modelsHousingYear of diagnosisMedicaid eligibilityCancer sitesData linkagePercentage of individualsMedicare entitlementPre-diagnosisOdds ratioStrength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting
Stackland S, Schnabel D, Dinan M, Presley C, Gross C. Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting. Journal Of The National Cancer Institute 2024, djae196. PMID: 39288939, DOI: 10.1093/jnci/djae196.Peer-Reviewed Original ResearchComprehensive genomic profilingComprehensive genomic profiling testCenter for Medical Technology PolicyClinical careClinical outcomesDiagnostic testsAssessed clinical outcomesOutcomes of patientsStrength of evidenceCourse of clinical careEfficacy of diagnostic testsNovel diagnostic testsPeer-reviewed literatureGenomic profiling testsFoundationOne CDxGenomic testingSolid tumorsStudy designGenomic alterationsGenomic profilingF1CDxCancer settingClinical utilityCancer typesCompare groupsTubal Sterilization Rates by State Abortion Laws After the Dobbs Decision
Xu X, Chen L, Desai V, Gross C, Pollack C, Schwartz P, Wright J. Tubal Sterilization Rates by State Abortion Laws After the Dobbs Decision. JAMA 2024, 332: 1204-1206. PMID: 39259564, PMCID: PMC11391354, DOI: 10.1001/jama.2024.16862.Peer-Reviewed Original ResearchRandomized Clinical Trials That Advance Health and Health Equity
Wang T, Corbie G, Allore H, Anderson T, Durant R, Ganguli I, Grady D, Gross C, Katz M, Mody L, Tripodis Y, Inouye S. Randomized Clinical Trials That Advance Health and Health Equity. JAMA Internal Medicine 2024, 184: 1011-1012. PMID: 39008289, DOI: 10.1001/jamainternmed.2024.3149.Peer-Reviewed Original ResearchCost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy
Forman R, Long J, Westvold S, Agnish K, McManus H, Leapman M, Hurwitz M, Spees L, Wheeler S, Gross C, Dinan M. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy. JNCI Cancer Spectrum 2024, 8: pkae067. PMID: 39133171, PMCID: PMC11376369, DOI: 10.1093/jncics/pkae067.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsOAA useAssociated with decreased adherenceRenal cell carcinomaAnticancer agentsDays of treatmentCombination therapyCell carcinomaStudy patientsInitial treatmentReal-world costsCombination groupImmunotherapyPatientsOOP costsTherapyTreatment typePercent daysPerspective of payersTreatmentClaims dataMedicare patientsAnalyzed differencesFee-for-service MedicareProgress in Lung Cancer Screening Adoption
Richman I, Gross C. Progress in Lung Cancer Screening Adoption. JAMA Internal Medicine 2024, 184: 902-903. PMID: 38857025, DOI: 10.1001/jamainternmed.2024.1673.Peer-Reviewed Original ResearchTrends in use of intensive care during hospitalizations at the end‐of‐life among older adults with advanced cancer
Jain S, Long J, Rao V, Law A, Walkey A, Prsic E, Lindenauer P, Krumholz H, Gross C. Trends in use of intensive care during hospitalizations at the end‐of‐life among older adults with advanced cancer. Journal Of The American Geriatrics Society 2024 PMID: 39090970, DOI: 10.1111/jgs.19119.Peer-Reviewed Original ResearchEnd-of-life hospitalizationsLife-sustaining treatmentEnd-of-lifeIntensity of careIn-hospital deathOlder adultsIntensive care unitAdvanced cancerRisk-adjusted hospitalEvaluate trendsIncreased intensity of careIntensive care unit useSEER-Medicare dataIntensive care unit careMultinomial regression modelsYear of diagnosisIntensive careHospital categoryMedicare beneficiariesSEER-MedicareHospitalization ratesCareCancer characteristicsNoninvasive ventilationHospitalReply to O. Saifi et al
Yu J, DeStephano D, Horowitz D, Gross C, Cheng S. Reply to O. Saifi et al. Journal Of Clinical Oncology 2024, 42: 3763-3764. PMID: 39079081, DOI: 10.1200/jco-24-01228.Peer-Reviewed Original ResearchAssociations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosisHarnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies
Miller J, Pelletiers W, Suttiratana S, Mensah M, Schwartz J, Ramachandran R, Gross C, Ross J. Harnessing policy to promote inclusive medical product evidence: development of a reference standard and structured audit of clinical trial diversity policies. BMJ Medicine 2024, 3: e000920. PMID: 39175919, PMCID: PMC11340651, DOI: 10.1136/bmjmed-2024-000920.Peer-Reviewed Original ResearchUS Food and Drug AdministrationFood and Drug AdministrationClinical trialsReference standardDrug AdministrationInternational Federation of Pharmaceutical ManufacturersTrial designPhases of clinical trialsEuropean Medicines AgencyEnrollment targetsPharmaceutical company websitesTrial recruitmentPatient populationImprove patient awarenessInternational FederationMedicines AgencyWorld Health OrganizationEligibility criteriaCompany policiesDiversity policiesStakeholder guidanceTrialsFDAPharmaceutical Research and Manufacturers of AmericaCharacteristics of participantsCosts of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront costTracking Physical Activity One Step at a Time
Gross C, Durant R. Tracking Physical Activity One Step at a Time. JAMA Internal Medicine 2024, 184: 726-726. PMID: 38767900, DOI: 10.1001/jamainternmed.2024.0898.Peer-Reviewed Original ResearchSystemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncology 2024, 10: 887-895. PMID: 38753341, PMCID: PMC11099840, DOI: 10.1001/jamaoncol.2024.1129.Peer-Reviewed Original ResearchNational Quality ForumQuintile 5Quintile 1Improve end-of-life careEnd-of-life careCohort studyNationwide population-based cohort studyPopulation-based cohort studyEnd of lifeElectronic health record databaseHealth care practicesColorectal cancerPopulation of patientsCox proportional hazards modelsAmerican Society of Clinical OncologyQuality ForumCare practicesOverall survivalPayment incentivesProportional hazards modelHighest quintileMultivariate Cox proportional hazards modelQuintileFlatiron HealthHazard ratioChanges in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare center